ESSENTIAL THROMBOCYTHEMIA
Clinical trials for ESSENTIAL THROMBOCYTHEMIA explained in plain language.
Never miss a new study
Get alerted when new ESSENTIAL THROMBOCYTHEMIA trials appear
Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTHEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control TerminatedThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for blood cancer patients: drug shows promise in controlling disease
Disease control TerminatedThis study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC